Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors

Cancer
Laura A PetrilloJustin F Gainor

Abstract

Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non-small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end-of-life care. This was a retrospective, single-site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS (≥2) at the start of ICI treatment with those who had PS 0 or 1 using Cox regression. Logistic regression was conducted to analyze the association between ICI use in the last 30 days of life and the use of end-of-life health care. The patient mean age at ICI initiation was 67 years (range, 37-91 years), and 35.4% of patients had PS ≥2. Most patients (80.8%) received ICI as second-line or later therapy. The median OS was 4.5 months in patients with PS ≥2 and 14.3 months in those with PS 0 or 1 (hazard ratio, 2.5; P < .0001). Among the patients who died (n = 184), 28.8% who had PS ≥2 received ICIs in their last 30 days of life compared with 10.8% of those who had PS 0 or 1 (P = .002). Receipt of ICI in the last 30 days of life was associated with decreased hospice referral (odds ratio, 0.29; P = .008) an...Continue Reading

References

Nov 1, 1994·Journal of Clinical Epidemiology·M CharlsonJ Gold
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Sep 12, 2003·The New England Journal of Medicine·James LubitzHarold Lentzner
Oct 18, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P C Stone, S Lund
Apr 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lowell E SchnipperDana S Wollins
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 10, 2015·Health Affairs·Ziad ObermeyerDavid M Cutler
Jul 24, 2015·JAMA Oncology·Holly G PrigersonPaul K Maciejewski
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Feb 20, 2016·BMJ Supportive & Palliative Care·Irene J Higginson
Apr 30, 2016·Journal of Health Politics, Policy and Law·Vincent Mor, Joan M Teno
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leora HornWilfried E E Eberhardt
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Nov 27, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Morgan R L LichtensteinJustin F Gainor
Jan 31, 2019·Journal of the American Geriatrics Society·Eugene MuchnikRonald J Maggiore
Apr 18, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PassaroFilippo de Marinis
Jun 4, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edward B GaronRina Hui
Nov 9, 2019·Journal of Palliative Medicine·Chad GlischLaurel Lyckholm

❮ Previous
Next ❯

Citations

Dec 9, 2020·Cancer Investigation·Ali Raza Khaki
May 18, 2020·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Valérie GounantElisabeth Quoix
Nov 2, 2020·Cancer Immunology, Immunotherapy : CII·Michael MarkUNKNOWN Swiss Group for Clinical Cancer Research (SAKK)
May 16, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Bernadatte ZimbwaSrinivas Kondalsamy-Chennakesavan
Jun 26, 2021·Journal of Translational Medicine·Daniele SantiniAlessio Cortellini
Jun 19, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Bartłomiej TomasikRafał Dziadziuszko
Jul 28, 2021·Advances in Medical Sciences·Damian MojsakRobert Marek Mróz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.